

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 9/72, 15/58		A1	(11) International Publication Number: WO 90/04023
			(43) International Publication Date: 19 April 1990 (19.04.90)
(21) International Application Number: PCT/EP89/01168 (22) International Filing Date: 6 October 1989 (06.10.89) (30) Priority data: 8823833.2 11 October 1988 (11.10.88) GB (71) Applicant (for all designated States except US): FARMITAL- IA CARLO ERBA S.R.L. [IT/IT]; Via Carlo Imbonati, 24, I-20159 Milan (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): BRANDAZZA, Anna [IT/IT]; Via Cesare Battisti, 45, I-26027 Rivolta D'Adda (IT). SARMIENTOS, Paolo [IT/IT]; Via Mosé, 24, I- 20100 Milan (IT). ORSINI, Gaetano [IT/IT]; Via Don Reina, 7, I-21013 Gallarate (IT). (74) Agents: KOLB, Helga et al.; Arabellastrasse 4, D-8000 München 81 (DE).		(81) Designated States: AT, AT (European patent), BE (Euro- pean patent), CH (European patent), DE (European pa- tent), DK, FI, FR (European patent), GB (European pa- tent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European pa- tent), SU, US. Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: PRODUCTION OF HUMAN PROUROKINASE



(57) Abstract

A method is provided for producing non-glycosylated single chain prourokinase (proUK). The method comprises cultivating bacterial strains of *E. coli* which have been transformed with plasmids carrying the cDNA sequence coding for proUK.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Fasso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

PRODUCTION OF HUMAN PROUROKINASE

The present invention relates to a recombinant DNA method of producing non-glycosilated single-chain prourokinase (hereinafter referred to as proUK). More particularly, it relates to a method of producing non-glycosilated proUK which comprises recovering mRNA from an established cell line, preparing cDNA based on said mRNA, inserting the cDNA into a vector, introducing the resulting plasmid into a bacterial cell to thereby produce a transformant and recovering non-glycosilated proUK from said bacterial cell. The invention concerns also certain expression plasmids employed in the above method.

Introduction

The increasing knowledge of the molecular interactions that regulate physiological fibrinolysis has lead to important implications in the understanding of the mechanisms that dissolve blood clots, and in the development of new thrombolytic agents.

In the human fibrinolytic system a proenzyme, plasminogen, can be activated to the active enzyme, plasmin, by several types of plasminogen activators (Collen, D. and Lijnen, H.R., CRC Critical Reviews in oncology/hematology, 4, n. 3, p. 249, 1986; Verstraete, M. and Collen, D.: Blood, 67, n. 6, p. 1529, 1986). Plasmin is the major protease responsible for the degradation of the fibrin component of a blood clot (Rakoczi, I., Wiman, B. and Collen, D.: Biochim. Biophys. Acta, 540, p. 295, 1978; Robbins, K.C.

Summaria, L., Hsieh, B.; and Shah, R.S.: J. Biol. Chem. 242, p. 2333, 1967; Wiman, B.; Eur. J. Biochem, 76, p. 129, 1977).

However, plasmin can also exert its proteolytic effect on several plasma proteins among which the components of the coagulation pathway fibrinogen, factor V and VIII (Collen, D. and Lijnen, H.R., CRC Critical Reviews in oncology/hematology, 4, n. 3, p. 249, 1986; Verstraete, M. and Collen, D.: Blood, 67, n. 6, p. 1529, 1986; Wiman, B., Lijnen, H.R. and Collen, D.; Biochim, Biophys. Acta, 579, p. 142, 1979).

Activation of plasminogen may occur at the systemic level, leading to circulating plasmin that is rapidly neutralized by alfa2-antiplasmin and thus not available for fibrinolysis (Collen, D. and Lijnen, H.R., CRC Critical Reviews in oncology/hematology, 4, n. 3, p. 249, 1986; Verstraete, M. and Collen, D.: Blood, 67, n. 6, p. 1529, 1986).

When the alfa2-antiplasmin level is markedly reduced, plasmin is less rapidly neutralized and can exert its proteolytic effects not only on fibrin, but also on the blood coagulation proteins as described previously.

Excessive lowering in the plasma concentrations of fibrinogen, factor V and VIII, together with the inhibitory effects exerted by some of the fibrinogen degradation products on the hemostatic process, on platelet aggregation and on fibrin polymerisation lead to hemostatic deficiency and subsequently to high bleeding risk (Latallo, Z.S. and Lopaciuk, S.; Thrombos. Diath. Haemouh., 56, p. 253, 1973; Totty, W.G., Gilula, L.A., Mc. Clennman, M., Ahmed, P., and Sherman, L. Radiology, 143, p. 59, 1982). On the other hand, activation of plasminogen may occur at the fibrin level (fibrin-bound plasminogen activation) leading to

fibrin-bound plasmin (Collen, D. and Lijnen, H.R., CRC Critical Reviews in oncology/hematology, 4, n. 3, p. 249, 1986; Verstraete, M. and Collen, D.: Blood, 67, n. 6, p. 1529, 1986) which is, instead, not affected by alfa2-antiplasmin and cannot induce systemic fibrinogenolysis.

Urokinase and streptokinase, the most commonly used plasminogen activators in conventional thrombolytic therapy in man, have no specific activity for fibrin. Both compounds activate relatively indiscriminately either circulating or fibrin-bound plasminogen (Zamarron, C., Lijnen, H.R., Van Hoef, B., and Collen, D., Thromb. Haemostas. 52, p. 19, 1984; Samama, M., and Kher, A. Sem. Hop. Paris. 61, n. 20. p. 1423, 1985). Therefore, the systemic haemostatic breakdown often encountered during treatment with streptokinase and urokinase and, consequently, the elevated bleeding risk have often hampered the widespread clinical use of these thrombolytic agents, despite their demonstrated clinical efficacy (Samama, M., and Kher, A. Sem. Hop. Paris, 61, n. 20. p. 1423, 1985; Maizel, A.S., and Bookstein, J.J.: Cardiovasc. Intervent. Radiol., 9, p. 236, 1986; Bell, W.R. Thromb. Haemostas., 35, p. 57, 1976; Acar, J., Vahanian, A., Michel, P.L., Slama, M., Cormier, B. and Roger, V., Seminars in Thromb. and Haemost., 13, n. 2, p. 186, 1987; Gruppo Italiano per lo studio della Streptochinase nell'infarto miocardico (GISSI); Lancet, 1, p. 397, 1986).

On the contrary, tissue-type plasminogen activator (t-PA) (Hoylaerts, M., Ryken, D.C., Lijnen, H.R. and Collen, D.J. Biol. Chem., 257, n. 6, p. 2912, 1982), and more recently prourokinase (pro-UK) (Husain, S.S., and Gurewich, V., Arch. Biochem. Biophys. 220 p. 31, 1983), both natural proteins, were shown to be weak

activators of the circulating plasminogen and, conversely, strong activators of the fibrin-bound plasminogen, without either systemic haemostatic breakdown or consumption of alfa2-antiplasmin and plasminogen, thus their clinical use may cause lesser bleeding risk.

The fibrin-specific thrombolytic activity of t-PA has been explained by its ability to bind fibrin through specific lysine binding sites, located in the triple-disulfide-bonded "kringle domains" of the molecule.

Consequently, fibrin-bound plasminogen could be activated without significant haemostatic breakdown (Collen, D., and Lijnen, H.R.: Haemostasis; 16, n. 3, p. 25, 1986). On the other hand, proUK (also denominated single chain urokinase type plasminogen activator, scu-PA) does not bind to fibrin, however it displays fibrin-specific thrombolytic activity without systemic hemostatic consumption (Pannell, R. and Gurewich, V., Blood, 67, p. 1215, 1986; Gurewich V., and Pannell, R.; Seminars in Thromb. and Haemost., 13, n. 2, p. 146, 1987; Lijnen, H.R., Zamarron, C., Blaber, M., Winbler, M.E., and Collen, D., J. Biol. Chem. 261, p. 1253, 1986).

Recombinant t-PA was submitted to multicenter clinical trials in patients with acute myocardial infarctions and was shown to be significantly more effective than streptokinase in the recanalization of obstructed coronary arteries (The European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator; Lancet, 1 p. 842, 1985; Sheehan, F.H. Braunwald, E., Canner, P., Doodge, H.T., Gore, J., Van Natta P., Passamani, E.R. Williams, D.O., Zaret, B.: Circulation, 75, 4, p. 817, 1987).

Prourokinase is at present in advanced clinical trials and is thought to be, at least, as effective as t-PA in terms of thrombolytic activity and safety (Van de Werf, F., Nobuhara, M., and Collen, D.: *Annals of Internal Medicine*, 104, p. 345, 1986; Van de Werf, F., Vanhaecke, J., De Geest, H., Verstraete, M., and Collen, D.: *Circulation*, 74, n. 5, p. 1066, 1986)

Background of the invention

Urokinase-type plasminogen activators (u-PAs) are found in at least three different forms in human urine, plasma and conditioned culture medium from a variety of cell lines. The first form to be characterized as u-PA consisted of a fibrinolytically active polypeptide of 410 amino acids, with an apparent molecular weight of 54000 daltons, containing two disulfide-linked chains (Gunzler, W.A., Steffens, G.J., Oetting, F., Kim, S.M.A. Frankus, E., and Flohé, L.: *Hoppe - Seyler's Z. Physiol.Chem.* 363, p. 1155, 1982).

The A-chain or light chain contains 157 amino acids and one triple disulfide-bonded "kringle" structure. This chain also contains a receptor binding domain for normal and neoplastic cells (monocytes, monocyte-like cells and A 431 epidermoid cells). The B chain or heavy chain (30000 daltons) consists of 253 amino acids and contains the catalytic domain.

This molecular form of u-PA is generally termed urokinase (UK), two chain urokinase (TC-UK) or high molecular weight urokinase (HMW-UK) (Gunzler, W.A., Steffens, G.J., Oetting, F., Buze, G., and Flohé, L.: *Hoppe-Seyler's Z. Physiol. Chem.* 363, p. 133, 1982).

The second form of u-PA has a molecular weight of 33000 daltons and results from proteolytic degradation of the HMW form by either plasmin or trypsin. It is called low

molecular weight urokinase (LMW-UK). Protein sequence determinations have revealed that LMW-UK is identical to HMW-UK except for the absence of the NH₂-terminal 135 amino acids that are specifically removed by the action of plasmin or trypsin (Steffens, G.J., Gunzler, W.A. Oetting, F., Frankus, E., and Flohé, L., Hoppe-Seyler's Z. Physiol. Chem., 363, p. 1043, 1982). Native prourokinase (proUK) is a single chain (54000 daltons) form of urokinase and is also termed single chain urokinase type plasminogen activator (scu-PA). As stated before, proUK displays a fibrin-specific thrombolytic activity and is therefore a better thrombolytic agent compared to the presently used high or low molecular weight urokinases.

In order to produce prourokinase, the authors of the present invention have developed a recombinant DNA procedure which allows the preparation of large amounts of the proUK polypeptidic chain.

Several methods have been described in the scientific and patent literature for the production of proUK (Holmes, W.E., Pennica, D., Blaber, M., Rey, M.W., Gunzler, W.A., Steffens, G.J. and Heynecker, H.L.; Biotechnology, 3, p. 923, 1985; European Patent Application 0092182). However, the method described within the text of the present invention exploits parameters known to be important for the expression of heterologous proteins in E. coli, but whose combination has never been applied before to the production of recombinant proUK.

The main parameters, whose combination contributes to the establishment of a recombinant strain of E. coli, able to produce proUK, and which represents the object of the present invention, are the E. coli promoter P_{trp}, the Shine-Dalgarno sequence MS-2 from the phage

MS-2, and E. coli strains of the type B as hosts for the expression of the human proUK gene (see below). Such combination is crucial. Substitution of one of these parameters with an alternative expression signal may not yield as much proUK.

Accordingly, object of the present invention is a method for the preparation of non glycosilated pro-UK, characterized in that non-glycosilated pro-UK is expressed under the control of the E. coli promoter P_{trp} and the Shine-Dalgarno sequence MS-2 by E. coli B.

Description of the production procedure

The present invention relates to the construction, by genetic engineering techniques, of strains of E. coli able to express the human proUK gene at high levels. Consequently, these recombinant strains are able to synthesize large amounts of the proUK polypeptidic chain.

In order to isolate said recombinant strains of the bacterium E. coli, it is necessary to go through a number of steps including:

- the isolation of the human cDNA gene coding for the desired proUK
- the insertion of said gene in an appropriate expression plasmid
- the transformation of selected strain of E. coli with the engineered plasmid and the cultivation of the transformants in appropriate conditions.

1) Cloning of the human cDNA gene coding for proUK

To obtain the cDNA clone coding for human prourokinase,

the authors have utilized the proteins sequence data published in the literature (Gunzler, W.A., Steffens, G.J., Oetting, F., Kim, S.M.A., Frankus, E., and Flohé, L.: Hoppe - Seyler's Z. Physiol.Chem., 363, p. 1155, 1982; Gunzler, W.A., Steffens, G.J., Oetting, F., Buze, G., and Flohé, L.: Hoppe-Seyler's Z. Physiol. Chem. 363, p. 133, 1982; Steffens, G.J., Gunzler, W.A., Oetting, F., Frankus, E., and Flohé, L., Hoppe-Seyler's Z. Physiol. Chem., 363, p. 1043, 1982).

Accordingly, specific probes have been prepared and an appropriate cDNA library has been screened.

Oligonucleotides coding for selected peptides of single-chain urokinase-type plasminogen activator (pro-UK) were chemically synthesized (Caruthers, M.H., Gassen, H.G. and Lang, J.A. (eds) Verlag-chimie, Weinheim, Deefield Beach, Basel, p. 71, 1982) to serve as specific probes to monitor enrichment of proUK mRNA and to select for clones containing prourokinase cDNA from an enriched cDNA library. The oligomers were 14 to 17 mer in lenght, and each one was synthetized either as unique sequence (named p7) or in pools containing two (named p1, p2, p3) or 16 (named p6) oligonucleotides as indicated in Fig. 1. The oligomers were tested for specificity to proUK by northern hybridization. For this analysis polyA-containing RNA was extracted from the HEP-3 epidermoid carcinoma (Miskin, R., Haemostasis (Switzerland), 11, No. suppl 1, p. 63, 1982). For each oligomer the temperature of the washing following the hybridization reaction was adjusted so as to be 2 to 5 degree C below the minimal melting temperature, as calculated according to Suggs et al. for hybridization to southern blots (Suggs, S.V., Hirose, T., Miyake, T., Kawashima, E.G., Johnson M.Y., Itakura, K. and Wallach, R.B., Developmental

Biology Using Purified Genes; Brown D.D. and Fox, C.F. (eds) Academic Press, New York, p. 638, 1981). In this text the five proUK probes, shown in Fig. 1, reacted with one common major carcinoma mRNA band of about 2.3 kb, which is the size expected for proUK mRNA.

Cloning took place using enriched mRNA fractions from the HEP-3 epidermoid carcinoma. RNA preparations were extracted and enriched about 3 fold on two successive sucrose gradients. cDNA was synthesized according to published procedures (Efstratiadis, A., Kafatos, F.C., Maxam, A.M. and Maniatis, T. Cell, 7, p. 279, 1976; Buell, G.N., Wickens, M.P., Payvar, F. and Schimke, R.T. J. Biol. Chem. 253, p. 2471, 1978) using oligo-dT as a primer. Longer molecules were isolated using polyacrilamide gel electrophoresis followed by electro-elution of the appropriate gel fractions. The cDNA was then extracted using standard phenol/chloroform extraction followed by ethanol precipitation.

These cDNA molecules were first ligated to EcoRI linkers and then cloned into the phage λ gt10 vector according to a modification of the technique of Davis (Maniatis, T., Fritsch, E.F., Sambrook, J.: Molecular cloning. A laboratory manual. Cold Spring Harbour Laboratory. Cold Spring Harbour, NY, 1982). By doing so, a library containing 2×10^5 pfu (plaque forming units) was constructed.

Half of the library was screened on duplicate filters, one filter with ^{32}P -labelled probe p1, and the counterpart filter with a mixture of probes p3 and p6. A total of 36 positive clones were obtained, seven of which were positive in the duplicate filters, thus indicating cDNA inserts corresponding to a large portion of the proUK coding sequence.

Recombinant phages that hybridized with the 3 probes were plaques purified using probe p1, and further

characterized by restriction mapping with EcoRI and by DNA sequencing. The fraction of the positive clones in the total cDNA library indicated that the frequency of prourokinase mRNA in the HEp-3 carcinoma is approximately 0.01%.

Sequence analysis of four proUK cDNA clones revealed that three of the clones had deletions or sequences not consistent with the amino acid sequence of the enzyme. Only one clone, λ Uc17, had a sequence with complete concordance with the known amino acid sequence.

However, λ Uc17 did not include the entire 3' non-coding end of the mRNA and was missing 30 nucleotides of the coding sequence. A full length pre-prourokinase cDNA clone was constructed by ligation of a 1325 bp λ Uc17 SmaI-BamHI fragment, containing the 5' non-coding region and the majority of the coding sequence, with a BamHI-EcoRI fragment containing the remaining missing 3' region from another clone λ Uc6 (Fig. 2).

This construct was ligated into the SmaI-EcoRI site of the plasmid vector pUN121 (Nilsson B., Uhlen M., Josephson S., Gatenbeck S. and Philipson L., *Nucleic Acid Research* 11, p. 8019, 1983), eliminating, thus, most of the cI gene, and given the name pcUK176 (Fig. 3).

The DNA sequence of the complete cDNA clone is depicted in Fig. 4. It consists of 2296 nucleotides, including 69 non-coding nucleotides at the 5' end, 1296 coding nucleotides, and 931 non-coding nucleotides at the 3' end, followed by a poly(A) tail of more than 80 residues.

The coding sequence starts with 60 bp coding for 20 amino acids comprising the "pre-prourokinase"

(Heyneker, H.L., Holmes, W.E. and Vehar, G.A. (1983). European Patent Application Publ. No. 0092182), and is followed by the sequence coding for the entire prourokinase protein, which is in complete concordance with the amino acid sequence.

The complete fragment has been checked by sequence and restriction analysis. The sequence coding for mature prourokinase has been inserted into the expression vector used for production.

2) Construction of the proUK expression plasmid

The original full length cDNA, present in pcUK176, was used to construct a prourokinase expression plasmid, named pFC44, in which the proUK gene is under the transcriptional and the translational control of the promoter Ptrp and of the "Shine-Dalgarno" sequence MS-2, respectively. The plasmid pFC44 is shown in fig. 7.

In order to obtain pFC44, several intermediate plasmids were constructed. Starting with pDS20 (Fig. 5) (Duester, G., Helfard, R.M. and Holmes, W.M.: Cell 30, p. 855, 1982), we have first replaced the EcoRI-HindIII fragment coding for the galactose operon promoter Pgal with the EcoRI-HindIII polylinker sequence from the M13 mp8 vector (Vieira, J. and Messing, I. Gene, 19, p. 259, 1982), obtaining a new plasmid, named pAB1 (Fig. 5).

The promoter Ptrp has been obtained from the plasmid pDR720 (bought from Pharmacia) as an EcoRI-SalI restriction fragment. This fragment has been inserted in the polylinker region of pAB1 between the EcoRI and the SalI site. By doing so, we have obtained a new plasmid, named pFC10 (Fig. 5).

pFC10 can be considered as the base vector into which we

have inserted the proUK gene as well as the "Shine-Dalgarno" sequence from the phage MS-2.

To achieve expression of mature prourokinase, it is necessary to fuse the proUK coding sequence, from the first codon of the mature protein to the initiator triplet ATG. This fusion must then be preceded by the "Shine-Dalgarno" sequence.

The ribosome binding site (RBS) from the bacterial phage MS-2 was known and its nucleotide sequence had already been published (Fiers, W., Contreras, R., Duerinck, F., Haegeman, G., Iserentant, D., Merregaert, J., Min Jou, W., Molemans, F., Raeymaekers, A., Van den Berghe, A., Volckaert, G. and Ysebaert, M. *Nature*, 260, p. 500, 1976).

It is thought to be a strong signal for an efficient translation of the mRNA. Therefore, we have chosen this region as translation signal for the production of proUK. In order to obtain the correct nucleotide fusion with the proUK gene, we have synthesized a double strand DNA region of the MS-2 RBS directly joined to the beginning of the proUK gene. A TaqI site is present on the 25th nucleotide of the mature proUK sequence. We have taken advantage of this site and isolated, by chemical synthesis, the following DNA sequence:

HindIII

MetSer

5'-AGCTTTAATAGACGCCGCCATTCAAACATGAGGATTACCCATGAGCA

3'-AATTATCTGCGGCCGGTAAGTTTGTACTCCTAATGGGTACTTCGT

TaqI

ATGAACTTCATCAAGTTCCAT-3'

TACTTGAAGTAGTTCAAGGTAGC-5'

which is flanked upstream by an HindIII site and down

stream by a *TaqI* site. The initiator codon ATG is shown in bold face. The sequence coding for the beginning of the mature proUK sequence is underlined.

The synthetic fragment has been used in a ligation reaction with the two following restriction fragments:

- the *TaqI*-*BglII* fragment from pcUK176 (Fig. 3), which carries the proUK sequence from nucleotide 155 to nucleotide 392 (see Fig. 4);

- the large *BamHI*-*HindIII* fragment from pFC10 (Fig. 5), which carries the antibiotic resistance to ampicillin as well as the promoter *P*_{trp}.

Through this construction, we have isolated a new plasmid, named pAB8, whose schematic map is shown in fig. 6. In this plasmid, the promoter *P*_{trp} and the MS-2 RBS are fused to the first 260 nucleotides of the mature proUK gene (corresponding to nucleotides 131-391 in Fig. 4). In addition, pAB8 has a unique *NcoI* site into which we have inserted the rest of the proUK sequence through a *NcoI*-*NcoI* restriction fragment from pcUK176. This ligation has caused the duplication of an *NcoI*-*BglII* fragment downstream of the proUK gene in the non-coding region. However, this duplication does not affect plasmid stability. Through this construction signals can now direct the synthesis of the complete proUK sequence (see Fig. 6).

All the plasmids, described so far, were selected in the *E. coli* K-12 host strain C-600 galK (ATCC 33955), on the basis of ampicillin resistance. Indeed, they carry the gene coding for β -lactamase, the enzyme responsible for the degradation of the antibiotic ampicillin in the culture medium. Early experiments have shown that pFC16 could be successfully inserted in *E. coli* type B strains and cause high level production of recombinant proUK.

However, to comply with international guidelines for the production of recombinant DNA-derived products, we have modified pFC16 to create a new tetracycline-resistant plasmid able to express the proUK gene at high levels. In particular, from the well-known plasmid pBR322 (Maniatis, T., Fritsch, E.F. Sambrook, J.: Molecular cloning. A laboratory manual. Cold Spring Harbour Laboratory. Cold Spring Harbour, NY. 1982)(Fig. 6), we have isolated a EcoRI-AvaI fragment where the sticky ends were filled in using the klenow fragment of DNA polymerase I (Perbal, B., A Wiley-Interscience Publication John Wiley and Sons, p. 231, 1984). This fragment was ligated to the larger AatII-PvuI fragment from pFC16, whose ends were made blunt by DNA polymerase I (Perbal, B., A Wiley-Interscience Publication John Wiley And Sons, p. 231, 1984). By doing so, we have replaced the amino terminal portion of the β -lactamase gene and its controlling sequence with the tetracycline-resistance gene. Following ligation the tetracycline resistance gene is in the same orientation as the proUK gene. Moreover, a new EcoRI site has been created at the junction between the PvuI and EcoRI sites, previously filled in. The new plasmid, pFC44 (see fig. 7), is the final construction that has been used for the production of recombinant prourokinase.

Plasmid pFC44 (tetracycline-resistant) and pFC16 (ampicillin resistant) are one of the objects of the present invention. The expression signals, present in these two plasmids, namely the promoter P_{trp} and the Shine-Dalgarno sequence "MS-2", have already been described in the literature for the expression of heterologous proteins (Remaut E., Stranssens P. and Fiers W. Nucl. Acid. Res. 11, p. 4677, 1983). However, their combination has never been applied before to the expression of the proUK gene.

3) Transformation of E.coli type B strains

The second main object of the present invention is the use of E. coli strains of the type B for the expression and production of prourokinase. Indeed, the authors of the present invention have found that insertion of plasmids pFC16 or pFC44 in type B strain of the bacterium E. coli brings to high level productions of the proUK polypeptidic chain. Interestingly, insertion of plasmids pFC16 or pFC44 in other strains of E. coli (type K-12, type C, type W, etc) does not yield as much proUK. Consequently, the host strain type seems to be crucial for the successful production of proUK.

Several type B strains of E. coli are available and can be used for successful expression of the proUK gene. Preferred strains are: ATCC 12407, ATCC 11303, NCTC 10537. Below is an example of transformation of strain NCTC 10537 with plasmid pFC44 and subsequent cultivation of the transformant.

Competent cells of strain NCTC 10537 were prepared using the calcium chloride procedure of Mandel and Higa (Mandel, M. and Higa, A.. J. Mol. Biol. 53, p. 154, 1970). Approximately 200 μ l of a preparation of these cells at 1×10^9 cells per milliliter were transformed with 2 μ l of plasmid DNA (approximate concentration 5 μ g/ml). Transformants were selected on plates of L-agar containing 12.5 μ g/ml tetracycline. Two small colonies were streaked with wooden tooth picks (each as three streaks about 1 cm long) onto L-agar containing the same antibiotic. After 12 hours incubation at 37°C, portions of the streaks were tested for human prourokinase production by inoculation onto 10 ml of LB medium (containing tetracycline at a concentration of 2.5 μ g/ml) and incubated overnight at 37°C. The following day the cultures were diluted 1:100 in M9 medium, containing the same concentration of tetracycline, and incubated for 6 hours at 37°C. Total

cell proteins from 250 μ l aliquots of culture (O.D.₅₅₀ = 1-1.5) were analysed by sodium dodecylsulfate polyacrylamide gel electrophoresis as described by Laemmli (Laemmli, U.K. Nature, 227, p. 680, 1970). A major protein band having a molecular weight corresponding to that of non-glycosylated human prourokinase (45000 daltons) was observed for the two independent samples (Fig. 8).

The set of streaks corresponding to colony no. 2 (clone 2) was chosen arbitrarily for further characterization and then selected as a proUK producing strain.

Materials and Methods

Growth Media: The media used were prepared using recipes as described by Maniatis et al. (Maniatis, T., Fritsch, E.F. Sambrook, J.: Molecular cloning. A laboratory manual. Cold Spring Harbour Laboratory. Cold Spring Harbour, NY 1982). LB Medium, LB agar and MacConkey agar were prepared using Difco Products. M9 medium is comprised of the following components: Na₂HPO₄, 6 grams/l; KH₂PO₄, 3 g/l; NaCl, 0.5 g/l; NH₄Cl, 1 g/l. After sterilization of the above components by autoclaving (1 atm.; 120°C for 20 min.), 1 ml of 1M MgSO₄, 0.1 ml of 1M CaCl₂, 16 ml of 25% Glucose, 20 ml of 0.5 mg/ml Thiamine (SIGMA) and 20 ml of 20% Casamino Acids (DIFCO) were added per litre. The above solution is sterilized by filtration.

Use of Restriction Endonucleases and Other Enzymes: Restriction endonucleases, T4 DNA Ligase and DNA Polymerase I (Klenow Fragment) were obtained from New England Biolabs and from Boehringer Mannheim and were used in conditions recommended by the manufacturer.

Preparation of Plasmid DNA: Plasmid DNA was prepared by

a method involving dye-buoyant density centrifugation based on the procedure of Birnboim and Doly (Birnboim, H.C. and Doly. J., Nucleic Acid Res. 7, p. 1513, 1979).

DNA sequence analysis: Sequence data were obtained using the Amersham M13 sequencing kit according to the instruction of the manufacturer. Briefly, this technique, based on the Sanger method (Sanger, F., Science, 214, p. 1205, 1981) consists of subcloning various restriction fragments in convenient M13 vectors (the "mp family") which can be obtained in their single strand configuration. After annealing the single strand forms with "universal primers", it is possible to copy the DNA template with DNA polymerase I (klenow fragment). By copying the template in the presence of the four dideoxynucleotides it is possible to cause random terminations of the chain elongation. The truncated fragments are then separated on denaturing polyacrylamide gels and the electrophoretic profile is evidenced by autoradiography.

Oligonucleotides: Synthetic oligonucleotides, utilized in plasmid constructions and as primers in DNA sequencing, were synthesized using the Applied Biosystem (ABI) DNA synthesizer 380B according to the ABI manual.

Other procedures: Procedures for agarose and polyacrilamide gel electrophoresis of nucleic acids were as described by Maniatis et al. (Maniatis, T., Fritsch, E.F. Sambrook, J.: Molecular cloning. A laboratory manual. Cold Spring Harbour Laboratory. Cold Spring Harbour, NY, 1982). Proteins were separated by polyacrylamide gel electrophoresis as described by Laemmli (Laemmli, U.K. Nature, 227, p. 680, 1970). DNA

was extracted from agarose gels by electrophoresis into dialysis bags and was concentrated by ethanol precipitation.

Legends to Figures

Fig. 1: The nucleotide sequence of probes P1, P2, P3, P6 and P7, the complementary mRNA sequence and the proUK peptides coded by the probes are depicted.

Fig. 2: The size and location of restriction endonuclease cleavage products were estimated by electrophoresis and confirmed by DNA sequence analysis. The filled region indicates the coding sequence of the mature proUK protein, the cross-hatched region represents the "pre-pro" peptide coding sequence and the open regions indicate the 5' and the 3' non-translated sequences. The 5' end of the mRNA is to the left. The lines below the restriction map indicate the contribution of the two partial clones λ Uc17 and λ Uc6.

Fig. 3: The EcoRI-SmaI fragment carrying the cDNA clone has been inserted in pUN121 replacing most of the cI gene. Plasmid pcUK176 is still tetracycline and ampicillin resistant. *cI represents an inactivated cI protein.

Fig. 4: The complete cDNA sequence of clone pcUK176 is depicted with the corresponding translated amino acid sequence. Restriction sites which have been used for plasmid constructions are underlined. Two polyadenylation sites at position 2264 and 2277 and the Serine residue at position 1 of the mature proUK

sequence are also underlined.

Fig. 5: In this figure four intermediate constructions are depicted. The starting plasmid, pDS20, carries the general background which, through the different intermediate plasmids, loses the promoter Pgal, the galK gene and the β -lactamase gene.

Fig. 6: Three additional intermediate constructions including plasmid pFC16 which expresses high level of proUK. For details, see the text.

Fig. 7: In pFC44 the mature proUK coding sequence is under control of the promoter P_{trp} and of the "ribosome binding site" from the phage MS-2. The tetracycline gene has been inserted at the place of the β -lactamase gene. pFC44 is therefore ampicillin sensitive.

Fig. 8: The samples were prepared and analysed as described in the text and loaded on a 12.5% SDS-polyacrylamide gel (acryl to bisacrylamide ratio 40:1). Lanes 1 and 2 contain material derived from two cultures of strain NCTC 10537 transformed with pFC44. The position of the recombinant prourokinase protein is indicated by the arrow. Lane 3 shows material derived from the control host strain NCTC 10537. A molecular weight standard is shown in lane 4.

Discussion and conclusions

The present invention relates to a recombinant DNA method for the production of non-glycosylated prourokinase. This method is based on the insertion of the human gene coding for proUK in bacterial strains of E. coli and the subsequent cultivation of said

transformed strains.

The production of heterologous proteins in E. coli is a well studied field of modern biotechnology (Harris T.J.R. and Emtage J.S. Microbiological Sciences, 3, p. 28-31, 1986). Today the molecular biologists dispose of several expression signals such as promoters, Shine-Dalgarno sequences, terminators, etc. that can be used for the protein of choice. The promoter is responsible for the synthesis of messenger RNA while the Shine-Dalgarno sequence should guarantee an efficient translation of the mRNA in polypeptidic chain.

The combination, however, of these parameters is an important feature in the heterologous gene expression. For example, fusion of an efficient Shine-Dalgarno sequence to different promoter regions can lead to different expression levels. In addition, the lenght of the restriction fragments carrying the expression signals often affects the levels of production (McCarthy J.E.G., Sebald W., Gross G. and Lammers R.; Gene, 41, p. 201, 1986).

The choice of the host strain is also a critical step in the development of an efficient method of production. It is, in fact, known that insertion of the same expression plasmid in different strains can lead to very different expression efficienciess (Harris T.J.R. and Emtage J.S. Microbiological Sciences, 3, p. 28-31, 1986).

While the expression signals described in the present invention were already known in the scientific literature, their combination had never been exploited before for the specific expression of human prourokinase. More particularly, plasmids pFC16 and pFC44 carry the proUK gene under control of the E. coli

promoter Ptrp and the phage Shine-Dalgarno sequence MS-2.

Consequently, the production method, disclosed within the text of the present invention, is based on expression plasmids essentially different from other expression plasmids previously described. These plasmids, pFC16 and pFC44, represent therefore one of the novelty aspects of the present invention and, as already said, are an object thereof.

In addition, the method here disclosed takes advantage of E. coli strains of the type B. The vast majority of the expression methods, described in the scientific literature, is based on strains of E. coli of the type K-12. Thus, the production of proUK in E. coli strains of the type B represents another novelty aspect of the present invention.

This second aspect is extremely important. The choice of the host organism can, in fact, affect the global production process at several steps.

For instance, fermentations at high biomass may dramatically be influenced by the type of host. The present inventors as well as other groups of researchers have consistently found that E. coli strains of the type B can be grown more easily than, e.g., K-12 strains. Insertion of the same expression plasmids, pFC16 or pFC44, in K-12 strains such as C600 generates recombinant strains, which cannot grow, in fermentators, as efficiently as the recombinant B strains. In other words, yields of recombinant non-glycosilated pro-UK are higher from B strains, when using the same expression plasmids.

Another important feature related to the choice of the host strain is the different nature of the bacterial contaminants during the pro-UK production process.

Undesired contaminants, such as proteases, could severely affect yields of the recombinant product. Interestingly, in 1986, Winkler and Blaber (Winkler, M.E., Blaber, M.: Biochemistry, 25, n. 14, p. 4041, 1986) have described a pro-UK production process based on the K-12 strain 294 (ATCC 31446).

In this process, the authors had to take several precautions to avoid proteolytic digestion of pro-UK. According to the authors these proteolytic activity was due to bacterial proteases from the host strain.

In contrast the use of B strains according to the present invention yields cell extracts with much lower proteolytic activity. In particular, it has been found that pro-UK extracted from the K-12 strain C600 is contaminated by urokinase to a higher extent compared to pro-UK from B strains.

In conclusion, the authors of the present invention, believe that the higher yields of recombinant pro-UK observed with the here described procedure compared with the prior art, represent an unpredictable result and an improvement over the known procedures.

Claims

1. A method for the preparation of non-glycosilated pro-UK, characterized in that non-glycosilated pro-UK is expressed under the control of the E. coli promoter Ptrp and the Shine-Dalgarno sequence MS-2 by E. coli B.
2. A method according to claim 1 wherein the non-glycosilated single chain prourokinase has a molecular weight of about 45000 daltons.
3. The method according to claim 1, characterized in that the E. coli B expresses primarily the sequence of pro-UK.
4. The method according to claim 1, characterized in that the cDNA sequence for pro-UK is obtained from mRNA of HEP-3 epidermoid carcinoma cells.
5. The method according to claim 1, characterized in that the promoter Ptrp constitutes of an EcoRI-SalI restriction fragment obtained from the plasmid pDR-720.
6. The method according to claim 1, characterized in that the sequence comprising the Shine-Dalgarno sequence MS-2, the ATG start codon and the beginning of the pro-UK gene, flanked upstream by a HindIII site and downstream by a TaqI site is as follows:

HindIII

5'-AGCTTTAATAGACGCCGCCATTCAAACATGAGGATTACCCATGAGC

3'-AATTATCTGCGGCCGGTAAGTTTGTACTCCTAATGGGTACTCG

TaqI


AATGAACTTCATCAAGTTCCAT-3'

TTACTTGAAGTAGTTCAAGGTAGC-5'

7. Expression plasmid FC-16 according to Fig. 6.
8. Expression plasmid FC-44 according to Fig. 7.

2/9

FIG. 2



3/9




FIG. 3

4/9

FIG. 4

1 SmaI
 CCCGGGCTCCGGGCTGCGGTCTCCTGCCGCAGCCACCGAGCCGCGTCTAGCGCCCCGACCTC
 50
 GCCACC ATG AGA GCC CTG CTG GCG CGC CTG CTT CTC TGC GTC CTG GTC
 Met Arg Ala Leu Leu Ala Arg Leu Leu Leu Cys Val Leu Val
 100
 GTG AGC GAC TCC AAA GGC AGC AAT GAA CTT CAT CAA GTT CCA TGC AAC
 Val Ser Asp Ser Lys Gly Ser Asn Glu Leu His Gln Val Pro Ser Asn
 150 TaqI
 TGT GAC TGT CTA AAT GGA GGA ACA TGT GTG TCC AAC AAG TAC TTC TCC
 Cys Asp Cys Leu Asn Gly Gly Thr Cys Val Ser Asn Lys Tyr Phe Ser
 200
 AAC AAT CAC TGG TGC AAC TGC CCA AAG AAA TTC GGA GGG CAG CAC TGT
 Asn Ile His Trp Cys Asn Cys Pro Lys Lys Phe Gly Gly Gln His Cys
 250
 GAA ATA GAT AAG TCA AAA ACC TGC TAT GAG GGG AAT GGT CAC TTT TAC
 Glu Ile Asp Lys Ser Lys Thr Cys Tyr Glu Gly Asn Gly His Phe Tyr
 300
 CGA GGA AAG GCC AGC ACT GAC ACC ATG GGC CGG CCC TGC CTG CCC TGG
 Arg Gly Lys Ala Ser Thr Asp Thr Met Gly Arg Pro Cys Leu Pro Trp
 350 NcoI
 AAC TCT GCC ACT GTC CTT CAG CAA ACG TAC CAT GCC CAC AGA TCT GAT
 Asn Ser Ala Thr Val Leu Gln Gln Thr Tyr His Ala His Arg Ser Asp
 400 BglII
 GCT CTT CAG CTG GGC CTG GGG AAA CAT AAT TAC TGC AGG AAC CCA GAC
 Ala Leu Gln Leu Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp
 450
 AAC CGG AGG CGA CCC TGG TGC TAT GTG CAG GTG GGC CTA AAG CCG CTT
 Asn Arg Arg Arg Pro Trp Cys Tyr Val Gln Val Gly Leu Lys Pro Leu
 500
 GTC CAA GAG TGC ATG GTG CAT GAC TGC GCA GAT GGA AAA AAG CCC TCC
 Val Gln Glu Cys Met Val His Asp Cys Ala Asp Gly Lys Lys Pro Ser
 550
 TCT CCT CCA GAA GAA TTA AAA TTT CAG TGT GGC CAA AAG ACT CTG AGG
 Ser Pro Pro Glu Glu Leu Lys Phe Gln Cys Gly Gln Lys Thr Leu Arg
 600
 CCC CGC TTT AAG ATT ATT GGG GGA GAA TTC ACC ACC ATC GAG AAC CAG
 Pro Arg Phe Lys Ile Ile Gly Gly Glu Phe Thr Thr Ile Glu Asn Gln
 650
 CCC TGG TTT GCG GCC ATC TAC AGG AGG CAC CGG GGG GGC TCT GTC ACC
 Pro Trp Phe Ala Ala Ile Tyr Arg Arg His Arg Gly Gly Ser Val Thr

5/9
FIG.4 cont'd

700
TAC GTG TGT GGA GGC AGC CTC ATC AGC CCT TGC TGG GTG ATC AGC GCC
Tyr Val Cys Gly Gly Ser Leu Ile Ser Pro Cys Trp Val Ile Ser Ala

750
ACA CAC TGC TTC ATT GAT TAC CCA AAG AAG GAG GAC TAC ATC GTC TAC
Thr His Cys Phe Ile Asp Tyr Pro Lys Lys Glu Asp Tyr Ile Val Tyr

800
CTG GGT CGC TCA AGG CTT AAC TCC AAC ACG CAA GGG GAG ATG AAG TTT
Leu Gly Arg Ser Arg Leu Asn Ser Asn Thr Gln Gly Glu Met Lys Phe

850
GAG GTG GAA AAC CTC ATC CTA CAC AAG GAC TAC AGC GCT GAC ACG CTT
Glu Val Glu Asn Leu Ile Leu His Lys Asp Tyr Ser Ala Asp Thr Leu

900
GCT CAC CAC AAC GAC ATT GCC TTG CTG AAG ATC CGT TCC AAG GAG GGC
Ala His His Asn Asp Ile Ala Leu Leu Lys Ile Arg Ser Lys Glu Gly

950
AGG TGT GCG CAG CCA TCC CGG ACT ATA CAG ACC ATC TGC CTG CCC TCG
Arg Cys Ala Gln Pro Ser Arg Thr Ile Gln Thr Ile Cys Leu Pro Ser

1000
ATG TAT AAC GAT CCC CAG TTT GGC ACA AGC TGT GAG ATC ACT GGC TTT
Met Tyr Asn Asp Pro Gln Phe Gly Thr Ser Cys Glu Ile Thr Gly Phe

1050
GGA AAA GAG AAT TCT ACC GAC TAT CTC TAT CCG GAG CAG CTG AAA ATG
Gly Lys Glu Asn Ser Thr Asp Tyr Leu Tyr Pro Glu Gln Leu Lys Met

1100
ACT GTT GTG AAG CTG ATT TCC CAC CGG GAG TGT CAG CAG CCC CAC TAC
Thr Val Val Lys Leu Ile Ser His Arg Glu Cys Gln Gln Pro His Tyr

1150
TAC GGC TCT GAA GTC ACC ACC AAA ATG CTA TGT GCT GCT GAC CCA CAA
Tyr Gly Ser Glu Val Thr Thr Lys Met Leu Cys Ala Ala Asp Pro Gln

1200
TGG AAA ACA GAT TCC TGC CAG GGA GAC TCA GGG GGA CCC CTC GTC TGT
Trp Lys Thr Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys

1250
TCC CTC CAA GGC CGC ATG ACT TTG ACT GGA ATT GTG AGC TGG GGC CGT
Ser Leu Gln Gly Arg Met Thr Leu Thr Gly Ile Val Ser Trp Gly Arg

1300
GGA TGT GCC CTG AAG GAC AAG CCA GGC GTC TAC ACG AGA GTC TCA CAC
Gly Cys Ala Leu Lys Asp Lys Pro Gly Val Tyr Thr Arg Val Ser His

BamHI
1350
TTC TTA CCC TGG ATC CGC AGT CAC ACC AAG GAA GAG AAT GGC CTG GCC
Phe Leu Pro Trp Ile Arg Ser His Thr Lys Glu Glu Asn Gly Leu Ala

6/9

FIG. 4 cont'd

CTC TGA GGGTCCCAGGGAGGAAACGGGCACCACCCGCTTTCTTGCTGGTTGTCATTTT
Leu end 1400

GCAGTAGAGTCATCTCCATCAGCTGTAAGAAGAGACTGGGAAGATAGGCTCTGCACAGATGGA
1450

TTTGCTGTGCCACCCACAGGGTGAACGACAATAGCTTTACCTCAGGCATAGGCCTGGGTG
1500

CTGGCTGCCAGACCCCTCTGGCCAGGATGGAGGGTGGTCTGACTCAACATGTTACTGACC
1550 1600

AGCAACTTGTCTTTTCTGGAAGCCTGCAGGAGTTAAAAAGGGCAGGGCATCTCCTGTG
1650

CATGGGTGAAGGGAGAGCCAGCTCCCCGACGGTGGGCATTGTGAGGCCCATGGTTGAGAAA
1700 NcoI

TGAATAATTTCCCAATTAGGAAGTGTAAACAGCTGAGGTCTCTTGAGGGAGCTTAGCCAATGTG
1750

GGAGCAGCGGTTTGGGGGAGCAGAGACCTAACGACTTCAGGGCAGGGCTCTGATATCCATG
1800 1850

AATGTATCAGGAAATATATATGTGTGTATGTTTGACACTTGTGTGTGGGCTGTGAGTGTA
1900

AGTGTGAGTAAGAGCTGGTGTCTGATTGTTAAGTCTAAATATTTCTTAAACTGTGTGGACTG
1950

TGATGCCACACAGAGTGGTCTTTCTGGAGAGGTTATAGGTCACTCCTGGGGCCTCTTGGGTCC
2000 2050

CCCACGTGACAGTGCCCTGGGAATGTATTATTCTGCAGCATGACCTGTGACCAGCACTGTCTCA
2100


GTTTCACTTTCACATAGATGTCCCTTTCTTGCCAGTTATCCCTTCCTTTAGCCTAGTTCAT
2150

CCAATCCTCACTGGGTGGGGTGAGGACCACTCCTTACACTGAATATTTATATTTCACTATTTT
2200

TATTTATATTTTGTAAATTTAAATAAAAGTGATCAATAAAATGTGATTTTCTG(A)_nGAATT
2250 EcoRI




C

FIG. 5



8/9

FIG. 6



9/9

FIG. 7





FIG. 8



INTERNATIONAL SEARCH REP RT

International Application No PCT/EP 89/01168

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC ⁵ : C 12 N 9/72, C 12 N 15/58		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁵	C 12 N	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched *		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP, A, 0236209 (GENETICA) 9 September 1987, see page 12, line 10 - page 13, line 20; page 15, lines 4-30; claims --	1,5
A	EP, A, 0210279 (SAGAMI CHEMICAL RESEARCH CENTER) 4 February 1987, see page 15, line 8 - page 16, line 5; claims --	1-3
A	Biotechnology, vol. 3, no. 10, October 1985 (New York, US), W.E. Holmes et al.: "Cloning and expression of the gene for pro-urokinase in Escherichia coli", pages 923-929, see the whole article cited in the application --	1-3
A	FEBS Letters, vol. 185, no. 2, June 1985, Elsevier Science Publishers B.V. (Biomedical Division) R. Renhof et al.: "Synthesis and functional activity of translation ./.	1,6
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
18th December 1989	09 FEB 1990	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	T.K. WILLIS	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
------------	--	----------------------

	initiation regions in mRNA", pages 277-281, see the whole article	
	--	
A	Nucleic Acids Research, vol. 11, no. 14, 1983, IRL Press (Oxford, GB), E. Remaut et al.: "Inducible high level synthesis of mature human fibroblast interferon in Escherichia coli", pages 4677-4688, see the whole article	1
	cited in the application	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 8901168

SA 31508

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 29/01/90
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0236209	09-09-87	FR-A- 2594845	28-08-87
		JP-A- 62265983	18-11-87
EP-A- 0210279	04-02-87	AU-A- 5390286	13-08-86
		JP-A- 62143686	26-06-87
		WO-A- 8604351	31-07-86